RxDoctor Payments Data

Paul Grunenwald, MD

Interventional Cardiology · Elk Grove Village, ILNPI 1427001627

Payments from drug & device makers

$706in general payments, 2019–2025

Across 26 payments — averaging $27.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$149
  • Biotronik Inc.$127
  • Livanova USA, Inc.$113
  • Shockwave Medical, Inc$78
  • Novartis$73
  • Medtronic$41
  • plus $126 from 5 others

What the payments were for

  • Food & beverage$706100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$706 in reported general payments places this provider in the 10th percentile of 303 interventional cardiology providers in Illinois.

See all interventional cardiology providers in Illinois

Medicare billing

Part B allowed, 2024
$261,362
Medicare patients
858
Services billed
3,135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban157$199,614
XareltoRivaroxaban54$71,944
EntrestoSacubitril/Valsartan55$65,291
Repatha SureclickEvolocumab14$19,778
BrilintaTicagrelor19$19,703
Atorvastatin Calcium842$9,575
Ezetimibe261$7,860
ClopidogrelClopidogrel Bisulfate315$4,295
Rosuvastatin Calcium254$3,932
Metoprolol Succinate232$3,703
Amlodipine Besylate233$2,441
Lisinopril188$2,034
Losartan Potassium154$1,931
Carvedilol206$1,930
Enalapril Maleate89$1,725

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$73$65,29155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 303 interventional cardiology providers in Illinois.

Other interventional cardiology in Elk Grove Village

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →